Please assess the completion status of the following clinical trial:

Trial Title: Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Axial spondyloarthritis according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis~* Sacroiliitis on conventional X-rays or Magnetic Resonance Imaging (MRI).~* Disease activity assessed by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \>40 mm despite treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAID).~* Clinical indication for tumor necrosis factor (TNF) inhibitor treatment by the treating physician.~Exclusion Criteria:~* No contraindications for TNF inhibitor~* No contraindications for MRI~* No contraindications in participation in a study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: None): Treatment: Injection Golimumab 50 mg every month on the same date

Based on this trial design, predict the completion outcome and termination type (if applicable).